Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Glimelius

Showing results (371-380 of 416) with videos related to

Pageof 42
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximabF Sclafani, A Roy, D Cunningham, et al.
The New England Journal of Medicine|November 14, 1997
Sexually transmitted infection as a cause of anal cancerM Frisch, B Glimelius, A J van den Brule, et al.
Cancer|January 15, 1994
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesisB G Sorbe, T Högberg, B Glimelius, et al.
Ugeskrift for Laeger|December 16, 1998
[Sexually transmitted infection as a cause of anal cancer]M Frisch, B Glimelius, A I van den Brule, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2005
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracilP Pfeiffer, H Sørbye, H Ehrsson, et al.
Anti-Cancer Drugs|August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumorsMaja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 25, 2000
Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's diseaseC Behrens, L B Travis, I I Wistuba, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trendsM F Ystgaard, T Å Myklebust, J Smeby, et al.
Journal of the National Cancer Institute|April 5, 1995
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphomaL B Travis, R E Curtis, B Glimelius, et al.
Journal of the National Cancer Institute|October 5, 1994
Risk of leukemia following treatment for non-Hodgkin's lymphomaL B Travis, R E Curtis, M Stovall, et al.
Pageof 42

Showing results (371-380 of 416) with videos related to

Sort By:
Pageof 42
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximabF Sclafani, A Roy, D Cunningham, et al.
The New England Journal of Medicine|November 14, 1997
Sexually transmitted infection as a cause of anal cancerM Frisch, B Glimelius, A J van den Brule, et al.
Cancer|January 15, 1994
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesisB G Sorbe, T Högberg, B Glimelius, et al.
Ugeskrift for Laeger|December 16, 1998
[Sexually transmitted infection as a cause of anal cancer]M Frisch, B Glimelius, A I van den Brule, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2005
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracilP Pfeiffer, H Sørbye, H Ehrsson, et al.
Anti-Cancer Drugs|August 13, 2002
Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumorsMaja J A de Jonge, B Glimelius, Jaap Verweij, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 25, 2000
Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's diseaseC Behrens, L B Travis, I I Wistuba, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trendsM F Ystgaard, T Å Myklebust, J Smeby, et al.
Journal of the National Cancer Institute|April 5, 1995
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphomaL B Travis, R E Curtis, B Glimelius, et al.
Journal of the National Cancer Institute|October 5, 1994
Risk of leukemia following treatment for non-Hodgkin's lymphomaL B Travis, R E Curtis, M Stovall, et al.
Pageof 42